ARTICLE | Product Development
Fresh $20M allows Azura to move lead candidate into pivotal testing for major cause of dry eye
Registrational study to start in 1Q21 in Australia, New Zealand
October 23, 2020 11:54 PM UTC
With a new $20 million financing that doubles what the company has raised to date, Israel’s Azura will be able to advance its lead program into a registrational study to address a major cause of dry eye syndrome.
Azura Ophthalmics Ltd. received the funding from current shareholders OrbiMed Advisors, TPG Biotech, Brandon Capital’s Medical Research Commercialisation Fund and Ganot Capital. Azura CEO Marc Gleeson told BioCentury that the company has now raised $38.4 million since its founding in 2014...
BCIQ Company Profiles